Suppr超能文献

在 HIV 感染中,结肠中齐多夫定耐药 HIV 的水平高于血液和其他胃肠道隔室。

Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection.

机构信息

Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.

出版信息

Retrovirology. 2010 Sep 13;7:74. doi: 10.1186/1742-4690-7-74.

Abstract

BACKGROUND

The gut-associated lymphoid tissue (GALT) is the largest lymphoid organ infected by human immunodeficiency virus type 1 (HIV-1). It serves as a viral reservoir and host-pathogen interface in infection. This study examined whether different parts of the gut and peripheral blood lymphocytes (PBL) contain different drug-resistant HIV-1 variants.

METHODS

Gut biopsies (esophagus, stomach, duodenum and colon) and PBL were obtained from 8 HIV-1 infected preHAART (highly active antiretroviral therapy) patients at three visits over 18 months. Patients received AZT, ddI or combinations of AZT/ddI. HIV-1 Reverse transcriptase (RT)-coding sequences were amplified from viral DNA obtained from gut tissues and PBL, using nested PCR. The PCR fragments were cloned and sequenced. The resulting sequences were subjected to phylogenetic analyses, and antiretroviral drug mutations were identified.

RESULTS

Phylogenetic and drug mutation analyses revealed differential distribution of drug resistant mutations in the gut within patients. The level of drug-resistance conferred by the RT sequences was significantly different between different gut tissues and PBL, and varied with antiretroviral therapy. The sequences conferring the highest level of drug-resistance to AZT were found in the colon.

CONCLUSION

This study confirms that different drug-resistant HIV-1 variants are present in different gut tissues, and it is the first report to document that particular gut tissues may select for drug resistant HIV-1 variants.

摘要

背景

肠道相关淋巴组织(GALT)是感染人类免疫缺陷病毒 1 型(HIV-1)的最大淋巴器官。它是感染时病毒储存库和宿主-病原体界面。本研究检查了肠道的不同部位和外周血淋巴细胞(PBL)是否含有不同的耐药 HIV-1 变体。

方法

在 18 个月的 3 次就诊中,从 8 名未接受高效抗逆转录病毒治疗(HAART)前的 HIV-1 感染患者中获得了肠道活检(食管、胃、十二指肠和结肠)和 PBL。患者接受 AZT、ddI 或 AZT/ddI 联合治疗。使用嵌套 PCR 从肠道组织和 PBL 中获得的病毒 DNA 扩增 HIV-1 逆转录酶(RT)编码序列。将 PCR 片段克隆并测序。对所得序列进行系统发育分析,并鉴定抗逆转录病毒药物突变。

结果

系统发育和药物突变分析显示,患者肠道内耐药突变的分布存在差异。RT 序列赋予的耐药水平在不同的肠道组织和 PBL 之间存在显著差异,并随抗逆转录病毒治疗而变化。赋予 AZT 最高耐药水平的序列存在于结肠中。

结论

本研究证实不同的耐药 HIV-1 变体存在于不同的肠道组织中,这是首次报道特定肠道组织可能选择耐药 HIV-1 变体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cd6/2949729/7acafac2551a/1742-4690-7-74-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验